a group of scientists from Cambridge University A has made a successful attempt artificial pancreas For use by patients suffering from diabetes, a device operated by an Algorithm and doubles the amount of time patients are in their target glucose range compared to standard treatment, potentially halving the time it takes to experience high glucose levels sugar,
In this regard, Dr. Charlotte Boughtonmember of the institute welcome-MRC of metabolic science from Cambridge UniversityIt is ensured thatThe artificial pancreas may offer a safe and effective approach to helping them, and the technology is easy to use and can be safely implemented at home.,
the device connects to a standard glucose monitor And an insulin bomb With an application developed by the team, called CamApps HXwho works with an Algorithm that predicts how much insulin Maintaining glucose levels in the target range is essential.
Prior to this study, the researchers worked to demonstrate that an artificial pancreas run by a similar algorithm was effective for patients living with it. diabetes type 1.
The challenge for this second part was bigger, and involved testing the device on a wider population that lived with it. diabetes type 2 and does not require kidney dialysis. Unlike the artificial pancreas used diabetes type 1This new version will be a completely closed loop system.
The researchers used several measures to assess how well the artificial pancreas worked. First, they measured the proportion of time they spent with their glucose levels within the target range of 3.9 to 10.0 mmol/L.
On average, patients using the artificial pancreas spent two-thirds (66%) of their time within the target range, compared with controls (32%); while the second measure was the proportion of time spent with glucose levels above 10.0 mmol/L.
In this case, patients taking the controller therapy spent two-thirds (67%) of their time with high glucose levels, which was cut in half (33%) when the artificial pancreas was used.
Additionally, the average glucose level dropped from 12.6 mmol/L when taking the control therapy to 9.2 mmol/L when using the artificial pancreas. In addition, the app also reduced levels of a molecule known as glycosylated hemoglobin or HbA1c,